Literature DB >> 20197107

Selective and potent furin inhibitors protect cells from anthrax without significant toxicity.

Albert G Remacle1, Katarzyna Gawlik, Vladislav S Golubkov, Gregory W Cadwell, Robert C Liddington, Piotr Cieplak, Sherri Z Millis, Roxane Desjardins, Sophie Routhier, Xue Wen Yuan, Witold A Neugebauer, Robert Day, Alex Y Strongin.   

Abstract

Furin and related proprotein convertases cleave the multibasic motifs R-X-R/K/X-R in the precursor proteins and, as a result, transform the latent proproteins into biologically active proteins and peptides. Furin is present both in the intracellular secretory pathway and at the cell surface. Intracellular furin processes its multiple normal cellular targets in the Golgi and secretory vesicle compartments while cell-surface furin appears to be essential only for the processing of certain pathogenic proteins and, importantly, anthrax. To design potent, safe and selective inhibitors of furin, we evaluated the potency and selectivity of the derivatized peptidic inhibitors modeled from the extended furin cleavage sequence of avian influenza A H5N1. We determined that the N- and C-terminal modifications of the original RARRRKKRT inhibitory scaffold produced selective and potent, nanomolar range, inhibitors of furin. These inhibitors did not interfere with the normal cellular function of furin because of the likely functional redundancy existing between furin and other proprotein convertases. These furin inhibitors, however, were highly potent in blocking the furin-dependent cell-surface processing of anthrax protective antigen-83 both in vitro and cell-based assays and in vivo. We conclude that the inhibitors we have designed have a promising potential as selective anthrax inhibitors, without affecting major cell functions. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20197107      PMCID: PMC2862824          DOI: 10.1016/j.biocel.2010.02.013

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  52 in total

1.  Comparison of multiple Amber force fields and development of improved protein backbone parameters.

Authors:  Viktor Hornak; Robert Abel; Asim Okur; Bentley Strockbine; Adrian Roitberg; Carlos Simmerling
Journal:  Proteins       Date:  2006-11-15

Review 2.  Proprotein convertases: lessons from knockouts.

Authors:  Nathalie Scamuffa; Fabien Calvo; Michel Chrétien; Nabil G Seidah; Abdel-Majid Khatib
Journal:  FASEB J       Date:  2006-10       Impact factor: 5.191

Review 3.  Proteolytic activation of bacterial toxins: role of bacterial and host cell proteases.

Authors:  V M Gordon; S H Leppla
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

Review 4.  Human plasma proteinase inhibitors.

Authors:  J Travis; G S Salvesen
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

5.  The synthesis of inhibitors for processing proteinases and their action on the Kex2 proteinase of yeast.

Authors:  H Angliker; P Wikstrom; E Shaw; C Brenner; R S Fuller
Journal:  Biochem J       Date:  1993-07-01       Impact factor: 3.857

Review 6.  Influenza viruses, cell enzymes, and pathogenicity.

Authors:  R Rott; H D Klenk; Y Nagai; M Tashiro
Journal:  Am J Respir Crit Care Med       Date:  1995-10       Impact factor: 21.405

7.  Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha 1-antitrypsin variant.

Authors:  E D Anderson; L Thomas; J S Hayflick; G Thomas
Journal:  J Biol Chem       Date:  1993-11-25       Impact factor: 5.157

8.  Antithrombin Pittsburgh: an alpha1-antitrypsin variant causing hemorrhagic disease.

Authors:  J H Lewis; R M Iammarino; J A Spero; U Hasiba
Journal:  Blood       Date:  1978-01       Impact factor: 22.113

Review 9.  Processing of viral glycoproteins by the subtilisin-like endoprotease furin and its inhibition by specific peptidylchloroalkylketones.

Authors:  W Garten; S Hallenberger; D Ortmann; W Schäfer; M Vey; H Angliker; E Shaw; H D Klenk
Journal:  Biochimie       Date:  1994       Impact factor: 4.079

10.  Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease.

Authors:  A Stieneke-Gröber; M Vey; H Angliker; E Shaw; G Thomas; C Roberts; H D Klenk; W Garten
Journal:  EMBO J       Date:  1992-07       Impact factor: 11.598

View more
  21 in total

1.  On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications.

Authors:  Frédéric Couture; François D'Anjou; Robert Day
Journal:  Biomol Concepts       Date:  2011-10-01

2.  Domain flexibility modulates the heterogeneous assembly mechanism of anthrax toxin protective antigen.

Authors:  Geoffrey K Feld; Alexander F Kintzer; Iok I Tang; Katie L Thoren; Bryan A Krantz
Journal:  J Mol Biol       Date:  2011-10-31       Impact factor: 5.469

3.  Identification of potent and compartment-selective small molecule furin inhibitors using cell-based assays.

Authors:  Bruno Ramos-Molina; Adam N Lick; Elias H Blanco; J Alejandro Posada-Salgado; Karina Martinez-Mayorga; Alan T Johnson; Guan-Sheng Jiao; Iris Lindberg
Journal:  Biochem Pharmacol       Date:  2015-05-21       Impact factor: 5.858

Review 4.  Designing inhibitors of anthrax toxin.

Authors:  Ekaterina M Nestorovich; Sergey M Bezrukov
Journal:  Expert Opin Drug Discov       Date:  2014-01-22       Impact factor: 6.098

Review 5.  An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

Authors:  Lernik Ohanjanian; Kenneth E Remy; Yan Li; Xizhong Cui; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2015-04-28       Impact factor: 6.206

6.  A femtomol range FRET biosensor reports exceedingly low levels of cell surface furin: implications for the processing of anthrax protective antigen.

Authors:  Katarzyna Gawlik; Albert G Remacle; Sergey A Shiryaev; Vladislav S Golubkov; Mingxing Ouyang; Yingxiao Wang; Alex Y Strongin
Journal:  PLoS One       Date:  2010-06-24       Impact factor: 3.240

7.  Furin targeted drug delivery for treatment of rhabdomyosarcoma in a mouse model.

Authors:  Katarina Hajdin; Valentina D'Alessandro; Felix K Niggli; Beat W Schäfer; Michele Bernasconi
Journal:  PLoS One       Date:  2010-05-03       Impact factor: 3.240

8.  Small molecule inhibitors of Bacillus anthracis protective antigen proteolytic activation and oligomerization.

Authors:  Alexander N Wein; Brian N Williams; Shihui Liu; Boris Ermolinsky; Daniele Provenzano; Ruben Abagyan; Andrew Orry; Stephen H Leppla; Michael Peredelchuk
Journal:  J Med Chem       Date:  2012-09-18       Impact factor: 7.446

9.  Design and Structure-Activity Relationship of a Potent Furin Inhibitor Derived from Influenza Hemagglutinin.

Authors:  Monika A Lewandowska-Goch; Anna Kwiatkowska; Teresa Łepek; Kévin Ly; Pauline Navals; Hugo Gagnon; Yves L Dory; Adam Prahl; Robert Day
Journal:  ACS Med Chem Lett       Date:  2021-02-05       Impact factor: 4.345

Review 10.  Why All the Fury over Furin?

Authors:  Essam Eldin A Osman; Alnawaz Rehemtulla; Nouri Neamati
Journal:  J Med Chem       Date:  2021-08-02       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.